Other languages Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Market Closed - London S.E. Other stock markets 11:35:17 2024-06-26 EDT			5-day change	1st Jan Change
5.2 ^GBX	-0.95%		-0.95%	+108.00%

06-10	AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs	AN
06-10	Allergy Therapeutics welcomes peanut allergy vaccine trial results	AN

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs	06-10
Allergy Therapeutics welcomes peanut allergy vaccine trial results	06-10
Abingdon Health buys IVDeology Holdings	05-07
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	05-07
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	04-03
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	03-27
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility	03-27
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue	03-27
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M	03-27
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024	03-27
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	03-27
Allergy Therapeutics starts dosing patients in peanut allergy trial	03-12
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate	03-12
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors	03-11
Allergy Therapeutics forecasts revenue drop but trials going well	02-14
Alliance Pharma appoints chair; FireAngel sales down	02-05
Scancell's Chief Development Officer to Step Down	02-05
Allergy Therapeutics resumes trading on AIM; annual revenue plunges	01-30
Allergy Therapeutics amends facility, plans warrant issue	12-27
Allergy Therapeutics Agrees Amendment to Loan Facility	12-27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Other languages

Filters